BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

  • BioCryst Pharmaceuticals, Inc. BCRX on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the consensus of $126.87 million.